Last close As at 03/09/2026
GBP0.91
▲ 2.40 (2.70%)
Market capitalisation
GBP237m
Research: Metals & Mining
Sylvania Platinum (Sylvania) delivered record FY26 4E PGM production of 95,885oz, up 18.4% from FY25 and ahead of both original and upgraded guidance, while chrome production of 50,317t met revised guidance. Record production combined with a strong PGM basket to more than double revenue to
| Year end | Revenue ($m) | PBT ($m) | EPS (¢) | DPS (p) | P/E (x) | Yield (%) |
|---|---|---|---|---|---|---|
| 6/25 | 104.2 | 27.7 | 7.73 | 2.75 | 16.6 | 2.9 |
| 6/26e | 227.2 | 108.5 | 30.47 | 6.00 | 4.2 | 6.3 |
| 6/27e | 238.0 | 101.4 | 28.00 | 6.92 | 4.6 | 7.3 |
| 6/28e | 266.8 | 121.5 | 33.55 | 9.55 | 3.8 | 10.1 |
Record Q426 production, a 28% higher average 4E basket price and a growing chrome
contribution has lifted FY26 revenue by 118% to
The Iran war has resulted in a downturn in PGM prices, and we have reset our forecasts
accordingly, cutting FY27 rhodium from
We cut our valuation by 12% to 171.2p/share, with the operating business at 160.6p and exploration assets at 10.7p. The implied FY26 P/E of 4.1x (3.2x for FY28) positions Sylvania well below the peer group range of 6–11x. This conservative perception of Sylvania is likely influenced by long-term production uncertainty, and we have taken a more conservative view in our own modelling. However, Sylvania’s rating may not fully account for its significant production successes to date and the almost 60% of its revenue derived from rhodium, ruthenium and iridium, which are exhibiting unique supply and demand dynamics compared to other PGMs.
Sylvania recorded a 4.4% increase in 4E platinum group metal (PGM) production during Q426 to 23,868oz (with a further 2,904oz work-in-progress, which will be recognised in revenue in Q127), resulting in total 6E PGM production of 30,474oz for the quarter. With the centralised PGM concentrate filtration plant in operation since November 2025, management expects work-in-progress to normalise at c 1,000oz to 1,500oz, so the FY26 carry-over was unusually high. Together with record PGM production in Q126 and Q226, and with a healthy Q226, its total 4E production for FY26 of 95,885oz is a new record, far surpassing 81,002oz in FY25, 72,704oz in FY24 and ahead of its guidance of 93,000oz (initial guidance was only 83,000oz to 86,000oz). The production record was underpinned by total PGM plant feed tons of 1.48m, an impressive 11.6% increase on FY25 (with c 7% of the increase from a maiden contribution from the Thaba joint venture (JV) and c 4.6% from increased Sylvania Dump Operations (SDO) feed efficiency). Chrome concentrate production of 50,317t was in line with revised guidance, albeit well below the initial guidance of 100,000–130,000t, due to flood-related ramp-up delays earlier in the year.
The average 4E PGM basket price for Q426 of $2,299 was 25% lower than in Q326 and 25.5% lower than our expectation. As a result, the company’s total revenue for the quarter of $48.5m was 38.4% down on Q325 (also affected by a reversal in the sales adjustment).
The company exhibited good cost control with SDO and group cash cost metrics down
between 4% and 7% in dollar terms, with total operating costs down 1.9% to
Capital expenditure picked up in the final quarter (to
During Q426, the cash balance increased by 6.2% from
Sylvania has grown 4E production per 1,000 shares in issue from 148oz in FY13 to 369oz in FY26, an increase of 149% over a period in which plant feed rose only 31%. The superior growth in production per share is thanks to the return on a sustained internal investment programme, as well as capital management. Plant recovery improved from c 40% in FY13 to c 57%, driven principally by the Project Echo secondary milling and flotation modules, the share of plant feed routed to the PGM circuit rose from c 46% to c 56%, and the continuous share buyback programme has reduced shares in issue by c 13% since FY15.
| Exhibit 2: 4E PGM production expressed per 1,000 issued Sylvania shares |
| Source: Edison Investment Research, Sylvania Platinum data |
Production per share has therefore compounded at more than twice the rate of production itself. We view this record as central to the investment case, as it demonstrates management's ability to grow the operating base independently of the PGM price cycle. When the PGM cycle is added into the mix, it amplifies Sylvania’s significant delivery as EPS increased 20-fold over the period from FY13 to FY26 (a compound annual growth rate of 26%). There was a structural bear market in PGMs until FY16 (the average PGM 4E basket increased 2.5x from FY13 to FY26). We will explore these production, price and capital management dynamics in greater depth in an outlook note in later in the year.
Sylvania’s SDO production has grown strongly over recent years, despite growing pressure on plant feed, which peaked at 2.56m tons in FY25. After a dip in PGM feed tons in FY25 (all SDO-related), which was affected by significant investment production improvements, combined PGM feed tons rose by an impressive 11.6% in FY26, with c 4.5% largely due to improvements in feed-head grade (resulting in a healthy rise in PGM feed relative to overall feed) but also supported by the maiden contribution from the JV (c 93,000t).
| Exhibit 3: JV pick-up to buffer against forecast SDO production decline |
| Source: Edison Investment Research |
We forecast SDO plant feed to be largely maintained at c 2.5m tons during FY27 and FY28, before it starts tapering off from FY29, on the back of feed declines for the Lannex, Millsell and Doornbosch operations, reducing to c 1.5m tons from FY32, when we forecast it to stabilise for the remainder of our explicit forecast period to FY40. We forecast combined plant feed to rise to a peak of 3.0m tons in FY28 on the back of the JV PGM ramp-up to full production.
We forecast combined PGM plant feed to hold at c 1.50m tons across FY27 to FY29, in line with management guidance that some SDO operations ran slightly above capacity in FY26, and we have trimmed our SDO PGM feed-grade assumption to 3.65g/t (from the 3.71g/t realised in FY26) to reflect the partial depletion of higher-grade third-party feed. On this basis, 4E PGM production remains broadly in line with the FY26 record, at c 94,100oz in FY27 (including the work-in-progress related to FY26) and c 91,800oz in FY28, recovering modestly to c 94,000oz in FY29 as the feed mix normalises, before the SDO run-off takes hold from FY30. Forecast production stabilises at c 65,000oz from FY32 until FY36, after which we allow for production from the JV to start moderating (in line with our 10-year life-of-mine assumption). Our 2E PGM and 6E PGM production forecasts follow a similar trajectory.
We have injected more conservatism into our production forecasts than in our previous modelling, to reflect the uncertainty of long-term production due to Sylvania’s dependence on feed from host mines where mineral resource estimates are not available as well as the current terms of the JV agreement being limited to 10 years. We have also taken a more conservative approach around PGM plant-feed grade and recovery, limiting further improvements from current levels. We believe that uncertainty around long-term production and efficiency may play a role in how investors perceive Sylvania, and we consider our lower forecasts as a more conservative base case against which attractive upside scenarios can be tested.
In our upcoming outlook note, we will explore alternative scenarios including a JV term extension, life-of-mine extensions for dump operations such as Tweefontein and Millsell, the continuation and potential growth of current arisings from host mines (including Mooinooi and Lesedi) and continued extraction efficiencies, especially as it relates to dump operations.
In our February 2026 report, we increased our PGM price forecasts on the back of the strong rally since late-December 2025. While the PGM rally peaked in February 2025, prior to the outbreak of the Iran war, elevated platinum and rhodium prices were sustained into mid-May 2026. Since then, platinum (down 20%) and rhodium (down 15%) have been under pressure, resulting in an update in our PGM forecasts. Ruthenium and iridium have remained strong and have been less affected by our forecast downgrades.
| Exhibit 4: Edison updated PGM price forecasts (average June year-end prices) |
| Source: Edison Investment Research, Austin Lawrence Gidon, LSEG Data & Analytics |
Our FY27 forecasts are cut materially across the 4E metals, with rhodium down from
Our long-term prices apply from FY31 and hold the FY30 levels broadly flat in constant-currency
terms, at
When the Iran war ends, we think that PGM prices across the board would strengthen as we believe AI demand will become dominant in all the PGMs over the next five years. We believe our forecasts, shown above, are therefore conservative. Following the outbreak of the Iran war, PGM prices fell as oil prices rose, the rationale being that internal combustion engine (ICE) vehicles would be more expensive to run while EVs would be much cheaper. As most of the palladium and rhodium produced is used in autocatalysts to restrict emissions and comply with stricter regulations in Europe and China over the next five years, palladium and rhodium prices fell initially.
Rhodium, ruthenium and iridium have insignificant above ground stocks while platinum and palladium have some months of these stocks left. All PGMs are forecast to be used in considerable amounts in AI-chip manufacture and data-storage systems where demand is rampant. Platinum is likely to be used in data storage, hard disc drives, AI-crystal production, AI servers (which run at high temperatures), manufacturing humanoid robot fingers that are more sensitive and increased high-end glassmaking. In the rhodium market, where stocks are depleted, demand is now being driven not only by autocatalysts, as demand returns for catalysed cars, but also by the demand for high-end high-quality glass for bases for AI chips. Palladium will be used extensively in multilayer-ceramic-capacitor production for AI applications, but as there are still several months of above-ground stocks available, its price is responding at a slower rate. Furthermore, even though there has been a shift to pure EVs in Europe because of the Iran war, EV sales are lagging hybrid-vehicle sales, and hybrid vehicles use ICEs, meaning that catalysed car sales are actually increasing in Europe and China. In the US, ICEs dominate and EV sales have plummeted. However, ICEs still dominate outside the US, with the result that PGM demand for autocatalysts is set to increase, with an extra lift from AI and other applications over the next few years.
Exhibit 5 shows the estimated contribution of each metal to Sylvania’s realised PGM revenue, after payability. Rhodium contributed 33–37% of realised revenue in each quarter of FY26 despite being only c 9% of 6E ounces, which makes it the single largest earnings driver. Ruthenium and iridium together contributed 11–15%, and their share is growing, with ruthenium's contribution roughly doubling since early FY25 as its price re-rated. We present these contributions net of payability. Sylvania realises c 74% of the gross 4E basket but only c 45% of the value of its ruthenium and iridium content, so ounce or gross-basket shares materially overstate the by-products’ contribution.
| Exhibit 5: Estimated contribution to 6E revenue (FY25 and FY26, quarterly) |
| Source: Edison Investment Research, Sylvania Platinum data |
Improved payability on the minor PGMs, which management has targeted through the centralised
filtration plant, is therefore a source of upside that requires no additional production.
Together with chrome, which contributed
Our FY27 revenue forecast has been cut by 40% to
We forecast capital expenditure of
During H126, Sylvania recognised a
Sylvania's dividend policy is to pay a minimum of 40% of adjusted free cash flow,
with one-third at the interim and two-thirds at the final, and our forecasts now apply
this policy directly. For FY26 we forecast a total ordinary dividend of 6p/share,
more than double the 2.75p/share of FY25, comprising the 2p interim already paid and
a forecast 4p final to be declared with the FY26 results. On our lower price deck,
the policy yields 6.9p/share in FY27 and 9.6p/share in FY28, with the shares yielding
c 6.6% on FY26. With the cash balance building well beyond operational requirements
from FY29, we see increasing potential for windfall distributions over and above the
ordinary dividend. The company also launched a
Our valuation declines by 14% to 167.7p/share, driven by the lower PGM price deck and our adoption of management's near-term production and dividend guidance. We now present the SDO and Thaba JV as a single operating valuation of 157.0p/share (previously 161.5p and 22.7p, respectively, a combined 15% lower), as the JV is now fully integrated into the group production, cost and cash flow. We carry exploration assets at book value of 10.7p/share following the Hacra impairment. Our valuation is based on a dividend discount model with a 10% discount rate over an explicit period to FY40, with a declining tail and no perpetuity, and it captures the distribution of the accumulating cash surplus over time.
The multiple implied by our new valuation and our FY26 EPS is an attractive 7.4x, rising to 8.0x on our FY27 forecast before falling to 6.7x on FY28. This compares well with Sylvania’s listed peers, which trade in a one-year forward multiple range of 6x to 11x. However, when considering the current Sylvania share price, which is at a 44% discount to our valuation, it appears undervalued compared to the peer group, with an FY26 price to earnings (P/E) multiple of only 4.2x (3.8x on a forward FY28 basis). All other things being equal, the market is effectively pricing the forward basket for Sylvania at c 25% below our forecasts.
Given the weight of the long-term prices in our valuation, we test them directly. A 10% move in the long-term rhodium price from FY31 moves the valuation by 3.6% (c 6p/share) in either direction, while a 10% move in long-term ruthenium and iridium prices together moves it by 1.4% (c 2.4p/share). We regard these as modest elasticities for a valuation at c 1.8x the share price, and they indicate that the investment case does not rest on any single long-term price assumption.
Exhibit 8 widens the test to the full forward curve, flexing each price by 10% from FY28 across all 14 forecast years. Rhodium remains the dominant lever at c 10p/share for a 10% move, followed closely by platinum at c 9p and chromite at c 5p, while iridium and ruthenium contribute c 2p each. Roughly 60% of each effect derives from the long-term price alone.
We would highlight chromite, which barely features in the equity narrative yet carries half the sensitivity of platinum, as the JV ramp-up has made it a genuine third leg of the revenue base.
General disclaimer and copyright
This report has been commissioned by Sylvania Platinum and prepared and issued by Edison, in consideration of a fee payable by Sylvania Platinum. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2026 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
OSE Immunotherapeutics’ key opinion leader (KOL) event summarised a broadened use case, and hence value offering, for lusvertikimab, its anti IL-7R monoclonal antibody, with discussion spanning IL-7R biology, the prior Phase II CoTikiS data in ulcerative colitis (UC) and the planned expansion into chronic pouchitis. Both CoTikiS doses met the week 10 primary endpoint, while extension data suggested durable responses through 34 weeks. KOLs Laurent Peyrin Biroulet and Maia Kayal expressed their encouragement from CoTikiS and support of the underlying disease biology and mode of action for translation to chronic pouchitis. The event also highlighted the unmet need in both indications, with OSE management communicating that the planned Phase IIa study in chronic antibiotic refractory pouchitis should establish a capital-efficient internal development opportunity in immuno-inflammation (I&I).